Management of Patients with Early-Stage Ovarian Cancer



Globally, the numbers of ovarian cancer are about 225,500 new cases and 140,200 deaths per year. In 2013, about 22,240 new cases of ovarian cancer will be diagnosed and 15,500 women will die of ovarian cancer in the USA. Early-stage ovarian cancer (International Federation of Gynecology and Obstetrics [FIGO] stages I to IIA) is approximately 30 % of patients with ovarian cancer; the disease is restricted to the true pelvis when it is diagnosed. Palpation of an adnexal mass during a pelvic examination is essential for diagnosis of ovarian tumor and cancer. Performing pelvic high resolution ultrasound examination is a useful noninvasive diagnostic test. In addition, measurement of cancer antigen 125 (CA-125) is important as it was found to be elevated in greater than 80 % of patients with epithelial ovarian cancer (EOC). The standard primary treatment for epithelial ovarian cancer involves pelvic and para-aortic lymphadenectomy, followed by adjuvant chemotherapy consisting of carboplatin and paclitaxel. Systematic lymphadenectomy resection and pathological examination of retroperitoneal lymph nodes have clinical significance for accurate assessment of staging and prognosis. This procedure may involve resection of para-aortic lesions, and therefore it may increase surgical morbidity, such as increased operation time, increased blood loss, lymph cyst formation, and edema in the leg. The surgical approach for EOC could be through laparotomy, laparoscopy, or robot-assisted laparoscopy, which has the advantage of being safe, better visualization of the abdominal and pelvis organs, minimal blood loss, and short hospital stay. Following surgery, patients with early ovarian cancer—FIGO stages I to IIA, except stage IA, grade 1—benefit from three to six cycles of platinum-based chemotherapy, in terms of both overall survival. Fertility-sparing surgery (FSS) for women of childbearing age with early-stage ovarian cancer is a desirable alternative to more radical approach. In addition, preservation of the adnexa and uterus is recommended in patients with non-epithelial tumors and epithelial borderline ovarian cancer.


Ovarian Cancer Epithelial Ovarian Cancer National Comprehensive Cancer Network Fertility Preservation Laparoscopic Staging 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society. Cancer facts and figures 2013. Atlanta, GA: American Cancer Society. 2013. Available at cancer/Detailed Guide/Ovarian-Cancer-Key-Statistics. Accessed 23 May 2013.
  2. 2.
    Goff BA. Ovarian cancer: screening and early detection. Obstet Gynecol Clin North Am. 2012;39(2):183–94.PubMedGoogle Scholar
  3. 3.
    Colombo N, Pecorelli S. What have we learned from ICON1 and ACTION? Int J Gynecol Cancer. 2003;13 Suppl 2:140–3.PubMedGoogle Scholar
  4. 4.
    Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, Bell J. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(3):307–11.PubMedGoogle Scholar
  5. 5.
    Zanetta G, Meni A, Brancatelli G, Chiari S, Lissoni AA, Ratti M, Buda A. Comparison of methods for monitoring young women with stage I borderline ovarian tumor after conservative surgery. Minerva Ginecol. 2001;53(1 Suppl 1):10–1.PubMedGoogle Scholar
  6. 6.
    Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol. 1988;72(5):775–81.PubMedGoogle Scholar
  7. 7.
    Morice P, Camatte S, Wicart-Poque F, Atallah D, Rouzier R, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D. Results of conservative management of epithelial malignant and borderline ovarian tumors. Hum Reprod Update. 2003;9(2):185–92. Review.PubMedGoogle Scholar
  8. 8.
    Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, Kose MF. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol. 2005;97(3):845–51.PubMedGoogle Scholar
  9. 9.
    Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Daraï E. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril. 2005;83(2):284–90.PubMedGoogle Scholar
  10. 10.
    Donnez J, Munschke A, Berliere M, Pirard C, Jadoul P, Smets M, Squifflet J. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril. 2003;79(5):1216–21.PubMedGoogle Scholar
  11. 11.
    Seracchioli R, Venturoli S, Colombo FM, Govoni F, Missiroli S, Bagnoli A. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors. Fertil Steril. 2001;76(5):999–1004.PubMedGoogle Scholar
  12. 12.
    Camatte S, Deffieux X, Castaigne D, Thoury A, Fourchotte V, Pautier P, Lhommé C, Duvillard P, Morice P. Laparoscopic treatment of borderline ovarian tumor: analysis of 54 patients and clinical outcomes. Gynecol Obstet Fertil. 2005;33(6):395–402.PubMedGoogle Scholar
  13. 13.
    Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol. 2000;95(4):541–7.PubMedGoogle Scholar
  14. 14.
    Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben-Baruch G. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer. 1998;82(1):141–6.PubMedGoogle Scholar
  15. 15.
    Kanazawa K, Suzuki T, Sakumoto K. Treatment of malignant ovarian germ cell tumors with preservation of fertility: reproductive performance after persistent remission. Am J Clin Oncol. 2000;23(3):244–8.PubMedGoogle Scholar
  16. 16.
    Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, Williams SD, Gynecologic Oncology Group. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2792–7.PubMedGoogle Scholar
  17. 17.
    Zanetta G, Bonazzi C, Cantù M, Binidagger S, Locatelli A, Bratina G, Mangioni C. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol. 2001;19(4):1015–20.PubMedGoogle Scholar
  18. 18.
    Perrin LC, Low J, Nicklin JL, Ward BG, Crandon AJ. Fertility and ovarian function after conservative surgery for germ cell tumors of the ovary. Aust N Z J Obstet Gynaecol. 1999;39(2):243–5.PubMedGoogle Scholar
  19. 19.
    Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol. 2003;101(2):251–7.PubMedGoogle Scholar
  20. 20.
    Adams G, Zekri J, Wong H, Walking J, Green JA. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG. 2010;117(12):1459–67.PubMedGoogle Scholar
  21. 21.
    Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2009;(3):CD004706.Google Scholar
  22. 22.
    Stuart GC, Kitchener H, Bacon M, Dubois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E, participants of 4th Ovarian Cancer Consensus Conference (OCCC), Gynecologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750–5.PubMedGoogle Scholar
  23. 23.
    Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2009;3, CD004706. doi: 10.1002/14651858.CD004706.pub3. Review.PubMedGoogle Scholar
  24. 24.
    Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators, European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003;95(2):113–25.PubMedGoogle Scholar
  25. 25.
    Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T, Farley JH, Gynecologic Oncology Group. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. Gynecol Oncol. 2008;111(3):487–95.PubMedGoogle Scholar
  26. 26.
    Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer. 2006;6:228.PubMedGoogle Scholar
  27. 27.
    Shimada M, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Minagawa Y, Ishihara K, Takeuchi Y, Okada M, Terakawa N. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer. 2005;15(4):601–5.PubMedGoogle Scholar
  28. 28.
    Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM, International Collaborative Ovarian Neoplasm 1, European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2):105–12.PubMedGoogle Scholar
  29. 29.
    Du XL, Parikh RC, Lairson DR, Giordano SH, Cen P. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Med Oncol. 2013;30(1):440. doi: 10.1007/s12032-012-0440-4.PubMedGoogle Scholar
  30. 30.
    Seliger G, Mueller LP, Kegel T, Kantelhardt EJ, Grothey A, Groe R, Strauss HG, Koelbl H, Thomssen C, Schmoll HJ. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19(8):1446–53.PubMedGoogle Scholar
  31. 31.
    Ozols RF, Markman M, Thigpen JT. ICON3 and chemotherapy for ovarian cancer. Lancet. 2002;360(9350):2086–7; author reply 2088.PubMedGoogle Scholar
  32. 32.
    Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin–a gynecologic oncology group study. J Clin Oncol. 2003;21(23):4350–5.PubMedGoogle Scholar
  33. 33.
    Bolis G, Scarfone G, Polverino G, Raspagliesi F, Tateo S, Richiardi G, Melpignano M, Franchi M, Mangili G, Presti M, Villa A, Conta E, Guarnerio P, Cipriani S, Parazzini F. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol. 2004;22(4):686–90.PubMedGoogle Scholar
  34. 34.
    Tropé CG, Kisic J, Vergote I. Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide. Eur J Gynaecol Oncol. 2000;21(3):255–9.PubMedGoogle Scholar
  35. 35.
    Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;102(3):432–9.PubMedGoogle Scholar
  36. 36.
    Querleu D, Leblanc E. Laparoscopic infrarenal para-aortic lymph node dissection for restaging of carcinoma of the ovary or fallopian tube. Cancer. 1994;73:1467–71.PubMedGoogle Scholar
  37. 37.
    Pomel C, Provencher D, Dauplat J, et al. Laparoscopic staging of early ovarian cancer. Gynecol Oncol. 1995;58:301–6.PubMedGoogle Scholar
  38. 38.
    Childers JM, Lang J, Surwit EA, Hatch KM. Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol. 1995;59:25–33.PubMedGoogle Scholar
  39. 39.
    Tozzi R, Köhler C, Ferrara A, Schneider A. Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol. 2004;93:199–203.PubMedGoogle Scholar
  40. 40.
    Leblanc E, Querleu D, Narducci F, Occelli B, Papageorgiou T, Sonoda Y. Laparoscopic staging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol. 2004;94:624–9.PubMedGoogle Scholar
  41. 41.
    Chi DS, Abu-Rustum NR, Sonoda Y, et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005;192:1614–9.PubMedGoogle Scholar
  42. 42.
    Ghezzi F, Cromi A, Uccella S, et al. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol. 2007;105:409–13.PubMedGoogle Scholar
  43. 43.
    Park JY, Bae J, Lim MC, et al. Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety. Int J Gynecol Cancer. 2008;18:1202–9.PubMedGoogle Scholar
  44. 44.
    Park JY, Kim DY, Suh DS, et al. Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol. 2008;15:2012–9.PubMedGoogle Scholar
  45. 45.
    Colomer AT, Jiménez AM, Bover Barceló MI. Laparoscopic treatment and staging of early ovarian cancer. J Minim Invasive Gynecol. 2008;15:414–9.PubMedGoogle Scholar
  46. 46.
    Nezhat FR, Ezzati M, Chuang L, Shamshirsaz AA, Rahaman J, Gretz H. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. Am J Obstet Gynecol. 2009;200:83.e1–6.Google Scholar
  47. 47.
    Lee M, Kim SW, Paek J, et al. Comparisons of surgical outcomes, complications, and costs between laparotomy and laparoscopy in early-stage ovarian cancer. Int J Gynecol Cancer. 2011;21:251–6.PubMedGoogle Scholar
  48. 48.
    Schreuder HW, Pattij TO, Zweemer RP, van Baal MW, Verheijen RH. Increasing experience in laparoscopic staging of early ovarian cancer. Gynecol Surg. 2012;9(1):89–96. doi: 10.1007/s10397-011-0692-6.PubMedGoogle Scholar
  49. 49.
    Schlaerth AC, Chi DS, Poynor EA, Barakat RR, Brown CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19(7):1199–204.PubMedGoogle Scholar
  50. 50.
    Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, Mangioni C. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997;104(9):1030–5.PubMedGoogle Scholar
  51. 51.
    Muzii L, Palaia I, Sansone M, Calcagno M, Plotti F, Angioli R, Panici PB. Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies. Fertil Steril. 2009;91(6):2632–7.PubMedGoogle Scholar
  52. 52.
    Eltabbakh GH. Effect of surgeon’s experience on the surgical outcome of laparoscopic surgery for women with endometrial cancer. Gynecol Oncol. 2000;78(1):58–61.PubMedGoogle Scholar
  53. 53.
    Jung US, Lee JH, Kyung MS, Choi JS. Feasibility and efficacy of laparoscopic management of ovarian cancer. J Obstet Gynaecol Res. 2009;35(1):113–8.PubMedGoogle Scholar
  54. 54.
    Nezhat FR, Ezzati M, Chuang L, Shamshirsaz AA, Rahaman J, Gretz H. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. Am J Obstet Gynecol. 2009;200(1):83–6.PubMedGoogle Scholar
  55. 55.
    Spirtos NM, Eisekop SM, Boike G, Schlaerth JB, Cappellari JO. Laparoscopic staging in patients with incompletely staged cancers of the uterus, ovary, fallopian tube, and primary peritoneum: a Gynecologic Oncology Group (GOG) study. Am J Obstet Gynecol. 2005;193(5):1645–9.PubMedGoogle Scholar
  56. 56.
    Kodama S, Tanaka K, Tokunaga A, Sudo N, Takahashi T, Matsui K. Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int J Gynaecol Obstet. 1997;56(2):147–15367.PubMedGoogle Scholar
  57. 57.
    Nagarsheth NP, Rahaman J, Cohen CJ, Gretz H, Nezhat F. The incidence of port-site metastases in gynecologic cancers. JSLS. 2004;8(2):133–9.PubMedGoogle Scholar
  58. 58.
    Tozzi R, Schneider A. Laparoscopic treatment of early ovarian cancer. Curr Opin Obstet Gynecol. 2005;17(4):354–8.PubMedGoogle Scholar
  59. 59.
    Vergote I, De BJ, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van GM, Trope CG. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357(9251):176–82.PubMedGoogle Scholar
  60. 60.
    Krivak TC, Elkas JC, Rose GS, Sundborg M, Winter WE, Carlson J, MacKoul PJ. The utility of hand-assisted laparoscopy in ovarian cancer. Gynecol Oncol. 2005;96(1):72–6.PubMedGoogle Scholar
  61. 61.
    Amara DP, Nezhat C, Teng NN, Nezhat F, Nezhat C, Rosati M. Operative laparoscopy in the management of ovarian cancer. Surg Laparosc Endosc. 1996;6(1):38–45.PubMedGoogle Scholar
  62. 62.
    Farghaly SA. Laparoscopic – assisted ovarian tumorectomy for patients with early- stage ovarian cancer: Farghaly’s procedure. JAAGL. 2001;8(3):S17. supplement.Google Scholar
  63. 63.
    Farghaly SA. Observations on port-site metastases following laparoscopic surgery for ovarian cancer. Am J Obstet Gynecol. 2004;190(5):1490.PubMedGoogle Scholar
  64. 64.
    Magrina JF, Zanagnolo V, Noble BN, et al. Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy. Gynecol Oncol. 2011;121:100–5.PubMedGoogle Scholar
  65. 65.
    Eskander RN, et al. Fertility preservation in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011;205(2):103–10.PubMedGoogle Scholar
  66. 66.
    Laurent I, Uzan C, Gouy S, et al. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern. Ann Surg Oncol. 2008;15:3561–6.PubMedGoogle Scholar
  67. 67.
    Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31:539–57.PubMedGoogle Scholar
  68. 68.
    Camatte S, Morice P, Thoury A, et al. Impact of surgical staging in patients with macroscopic ‘stage I’ ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer. 2004;40:1842–9.PubMedGoogle Scholar
  69. 69.
    Desfeux P, Camatte S, Chatellier G, et al. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol. 2005;98:390–5.PubMedGoogle Scholar
  70. 70.
    Cho YH, Kim DY, Kim JH, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol. 2006;103:878–82.PubMedGoogle Scholar
  71. 71.
    Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol. 2005;123(Suppl):S13–57.PubMedGoogle Scholar
  72. 72.
    Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol. 2006;100:185–91.PubMedGoogle Scholar
  73. 73.
    Morice P, Camatte S, El Hassan J, et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril. 2001;75:92–6.PubMedGoogle Scholar
  74. 74.
    Weinstein D, Polishuk WZ. The role of wedge resection of the ovary as a cause for mechanical sterility. Surg Gynecol Obstet. 1975;141:417–8.PubMedGoogle Scholar
  75. 75.
    Park JY, Kim DY, Kim JH, et al. Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol. 2009;113:75–82.PubMedGoogle Scholar
  76. 76.
    Farghaly SA. Video laparoscopic fertility- sparing surgery in patients with low malignant potential (LMP) ovarian tumors: Farghaly’s technique. Min Inv Gynecol. 2008;15(6):84S.Google Scholar
  77. 77.
    Romagnolo C, Gadducci A, Sartori E, et al. Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol. 2006;101:255–60.PubMedGoogle Scholar
  78. 78.
    Maneo A, Vignali M, Chiari S, et al. Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol. 2004;94:387–92.PubMedGoogle Scholar
  79. 79.
    Tinelli R, Malzoni M, Cosentino F, et al. Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors. Fertil Steril. 2009;92:736–41.PubMedGoogle Scholar
  80. 80.
    Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20:1319–30.PubMedGoogle Scholar
  81. 81.
    Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol. 1996;20:1331–45.PubMedGoogle Scholar
  82. 82.
    Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111–28.PubMedGoogle Scholar
  83. 83.
    Deavers MT, Gershenson DM, Tortolero-Luna G, et al. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol. 2002;26:1129–41.PubMedGoogle Scholar
  84. 84.
    Laurent I, Uzan C, Gouy S, et al. Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern. BJOG. 2009;116:860–2.PubMedGoogle Scholar
  85. 85.
    Abusief ME, Hornstein MD, Jain T. Assessment of United States fertility clinic websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines. Fertil Steril. 2007;87:88–92.PubMedGoogle Scholar
  86. 86.
    Gallot D, Pouly JL, Janny L, et al. Successful transfer of frozen-thawed embryos obtained immediately before radical surgery for stage IIIa serous borderline ovarian tumour: case report. Hum Reprod. 2000;15:2347–50.PubMedGoogle Scholar
  87. 87.
    Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364:1405–10.PubMedGoogle Scholar
  88. 88.
    Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006;86:70–80.PubMedGoogle Scholar
  89. 89.
    Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353:318–21.PubMedGoogle Scholar
  90. 90.
    Demeestere I, Simon P, Buxant F, Robin V, Fernandez SA, Centner J, et al. Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report. Hum Reprod. 2006;21:2010–4.PubMedGoogle Scholar
  91. 91.
    Kim SS, Radford J, Harris M, Varley J, Rutherford AJ, Lieberman B, et al. Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod. 2001;16:2056–60.PubMedGoogle Scholar
  92. 92.
    Fain-Kahn V, Poirot C, Uzan C, Prades M, Gouy S, Genestie C, et al. Feasibility of ovarian cryopreservation in borderline ovarian tumours. Hum Reprod. 2009;24:850–5.PubMedGoogle Scholar
  93. 93.
    Navot D, Fox JH, Williams M, Brodman M, Friedman Jr F, Cohen CJ. The concept of uterine preservation with ovarian malignancies. Obstet Gynecol. 1991;78:566–8.PubMedGoogle Scholar
  94. 94.
    Lawal AH, B-Lynch C. Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation-embryo transfer. Br J Obstet Gynaecol. 1996;103:931–2.PubMedGoogle Scholar
  95. 95.
    Kwon YS, Hahn HS, Kim TJ, Lee IH, Lim KT, Lee KH, et al. Fertility preservation in patients with early epithelial ovarian cancer. J Gynecol Oncol. 2009;20(1):44–7.PubMedGoogle Scholar
  96. 96.
    Borgfeldt C, Iosif C, Måsbäck A. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2007;134(1):110–4.PubMedGoogle Scholar
  97. 97.
    Kajiyama H, Shibata K, Mizuno M, et al. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 2011;105(9):1288–94.PubMedGoogle Scholar
  98. 98.
    Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible? Hum Reprod. 2011;26(12):3297–302.PubMedGoogle Scholar
  99. 99.
    Kajiyama H, Shibata K, Suzuki S, et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol. 2010;36(4):404–8.PubMedGoogle Scholar
  100. 100.
    Braicu E-I, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer. 2011;105(12):1818–24.PubMedGoogle Scholar
  101. 101.
    Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116(6):1462–8.PubMedGoogle Scholar
  102. 102.
    Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010;94(2):638–44.PubMedGoogle Scholar
  103. 103.
    Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007;96(12):1808–16.PubMedGoogle Scholar
  104. 104.
    Hancke K, Isachenko V, Isachenko E, Weiss JM. Prevention of ovarian damage and infertility in young female cancer patients awaiting chemotherapy-clinical approach and unsolved issues. Support Care Cancer. 2011;19(12):1909–19.PubMedGoogle Scholar
  105. 105.
    Morice P, Leblanc E, Rey A, Querleu D, Blanchot J, Duvillard P, et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Française d’Oncologie Gynécologique). Hum Reprod. 2005;20(5):1379–85.PubMedGoogle Scholar
  106. 106.
    Oven Ustaalioglu BB, Bilici A, Kefeli U, Seker M, Salepci T, Unal O, Gumus M. A retrospective analysis of women’s chances to become pregnant after completion of chemotherapy: a single center experience. J BUON. 2011;16(2):349–52.PubMedGoogle Scholar
  107. 107.
    Tan SJ, Yeh YC, Shang WJ, Wu GJ, Liu JY, Chen CH. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model. Eur J Obstet Gynecol Reprod Biol. 2010;149(2):182–5.PubMedGoogle Scholar
  108. 108.
    Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for Efertility preservation in women during chemotherapy. Hum Reprod Update. 2008;14(6):543–52.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, The Weill Cornell Medical College/Weill Cornell Graduate School of Medical Sciences, and The New York Presbyterian Hospital- Weill Cornell Medical CenterCornell UniversityNew YorkUSA

Personalised recommendations